- Home
- MDV vs IKT Comparison
MDV vs IKT Comparison
Compare MDV & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDV
- IKT
- Stock Information
- Founded
- MDV 2015
- IKT 2008
- Country
- MDV United States
- IKT United States
- Employees
- MDV N/A
- IKT N/A
- Industry
- MDV Transportation Services
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- MDV Consumer Discretionary
- IKT Health Care
- Exchange
- MDV Nasdaq
- IKT Nasdaq
- Market Cap
- MDV 149.1M
- IKT 131.6M
- IPO Year
- MDV 2022
- IKT 2020
- Fundamental
- Price
- MDV $14.59
- IKT $1.66
- Analyst Decision
- MDV
- IKT Buy
- Analyst Count
- MDV 0
- IKT 2
- Target Price
- MDV N/A
- IKT $8.00
- AVG Volume (30 Days)
- MDV 41.2K
- IKT 135.7K
- Earning Date
- MDV 08-05-2025
- IKT 08-13-2025
- Dividend Yield
- MDV 7.95%
- IKT N/A
- EPS Growth
- MDV N/A
- IKT N/A
- EPS
- MDV N/A
- IKT N/A
- Revenue
- MDV $46,738,000.00
- IKT N/A
- Revenue This Year
- MDV $2.21
- IKT N/A
- Revenue Next Year
- MDV $4.45
- IKT N/A
- P/E Ratio
- MDV N/A
- IKT N/A
- Revenue Growth
- MDV N/A
- IKT N/A
- 52 Week Low
- MDV $13.62
- IKT $1.12
- 52 Week High
- MDV $18.11
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- MDV 52.07
- IKT 35.43
- Support Level
- MDV $14.01
- IKT $1.91
- Resistance Level
- MDV $14.61
- IKT $2.07
- Average True Range (ATR)
- MDV 0.31
- IKT 0.11
- MACD
- MDV 0.07
- IKT -0.03
- Stochastic Oscillator
- MDV 62.37
- IKT 0.00
About MDV Modiv Industrial Inc. Class C
Modiv Industrial Inc is a pioneer in the direct-to-consumer commercial real estate product industry. It provides individual investors access to real estate and real estate-related investments designed to provide both income and long-term growth. The Company has invested in single-tenant income-producing properties. Its current business consists of owning, managing, operating, leasing, acquiring, investing in and disposing of commercial real estate assets utilized for industrial manufacturing, as well as a few non-core assets. All of the company's consolidated revenues are derived from company's consolidated real estate properties.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.